ATE302757T1 - Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität - Google Patents

Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität

Info

Publication number
ATE302757T1
ATE302757T1 AT01931766T AT01931766T ATE302757T1 AT E302757 T1 ATE302757 T1 AT E302757T1 AT 01931766 T AT01931766 T AT 01931766T AT 01931766 T AT01931766 T AT 01931766T AT E302757 T1 ATE302757 T1 AT E302757T1
Authority
AT
Austria
Prior art keywords
indanylimidazoles
alpha2 adrenergic
adrenergic activity
new polycyclic
alpha2
Prior art date
Application number
AT01931766T
Other languages
English (en)
Inventor
Jari Ratilainen
Paavo Huhtala
Arto Karjalainen
Arja Karjalainen
Antti Haapalinna
Raimo Virtanen
Jyrki Lehtimaeki
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of ATE302757T1 publication Critical patent/ATE302757T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01931766T 2000-05-08 2001-05-07 Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität ATE302757T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20001065 2000-05-08
PCT/FI2001/000434 WO2001085698A1 (en) 2000-05-08 2001-05-07 New polycyclic indanylimidazoles with alpha2 adrenergic activity

Publications (1)

Publication Number Publication Date
ATE302757T1 true ATE302757T1 (de) 2005-09-15

Family

ID=8558343

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01931766T ATE302757T1 (de) 2000-05-08 2001-05-07 Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität

Country Status (16)

Country Link
US (1) US6362211B2 (de)
EP (1) EP1280779B1 (de)
JP (1) JP2003532712A (de)
AT (1) ATE302757T1 (de)
AU (2) AU2001258469B2 (de)
CA (1) CA2408290A1 (de)
CZ (1) CZ20023674A3 (de)
DE (1) DE60112917T2 (de)
ES (1) ES2247107T3 (de)
IL (1) IL152401A0 (de)
NO (1) NO20025323L (de)
NZ (1) NZ522274A (de)
PE (1) PE20011321A1 (de)
PT (1) PT1280779E (de)
RU (1) RU2002132883A (de)
WO (1) WO2001085698A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835834B1 (fr) * 2002-02-14 2004-04-02 Pf Medicament Nouveaux derives de tricyclo-imidazolines, leur procede de preparation et leur utilisation a titre de medicaments
US8188126B2 (en) * 2002-05-16 2012-05-29 Pierre Fabre Medicament Imidazolic compounds and use thereof as alpha-2 adrenergic receptors
FR2839719B1 (fr) 2002-05-16 2004-08-06 Pf Medicament Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments
EP2323734A1 (de) * 2008-08-04 2011-05-25 Schering Corporation Cyclopropylchromen-derivate als modulatoren des alpha-2c-rezeptors
US10826751B2 (en) * 2009-12-28 2020-11-03 Telefonaktiebolaget Lm Ericsson (Publ) Management of functional interconnections between application modules on resource nodes in a social web
EP3646031B1 (de) * 2017-06-26 2023-09-20 Bio-Rad Europe GmbH Serielles in situ verdünnungsverfahren

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
FI81092C (fi) * 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
GB2225782A (en) * 1988-12-09 1990-06-13 Farmos Group Limited Imidazole derivatives useful for treatment of diabetes
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives

Also Published As

Publication number Publication date
RU2002132883A (ru) 2004-04-20
CA2408290A1 (en) 2001-11-15
AU5846901A (en) 2001-11-20
EP1280779A1 (de) 2003-02-05
PT1280779E (pt) 2005-11-30
JP2003532712A (ja) 2003-11-05
DE60112917D1 (de) 2005-09-29
ES2247107T3 (es) 2006-03-01
NZ522274A (en) 2004-11-26
CZ20023674A3 (cs) 2003-09-17
EP1280779B1 (de) 2005-08-24
NO20025323D0 (no) 2002-11-06
NO20025323L (no) 2002-11-06
US20020013356A1 (en) 2002-01-31
WO2001085698A1 (en) 2001-11-15
US6362211B2 (en) 2002-03-26
AU2001258469B2 (en) 2005-04-14
PE20011321A1 (es) 2002-01-03
IL152401A0 (en) 2003-05-29
DE60112917T2 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
MX9800867A (es) Halogenobencimidazoles y su empleo como microbicidas.
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
NO20025590D0 (no) Fenylglycin-derivater
ATE270817T1 (de) Fungizide
DK0944643T3 (da) Oxyiminopregnancarbolactoner.
DE69834508D1 (de) Aptoptoseinhibitoren
TR200402069T4 (tr) Difenilüre türevleri ve bunların alfa 2/5-HT2c antagonisti olarak kullanılması
DE60012809D1 (de) 2-Pyridinylguanidine als Urokinase Inhibitoren
DE60316672D1 (de) Polycyclische verbindungen als potenten alpha2-adrenoceptor antagonisten
EA199900935A1 (ru) Соединения индазоламида в качестве серотонинергических агентов
ATE175661T1 (de) Benzamid-derivate als vasopressin-antagonisten
ATE359073T1 (de) Benzylidenthiazolidindione und ihre verwendung als antimykotische mittel
DK1042319T3 (da) Dihydrobenzofuraner
ATE302772T1 (de) 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung
PT1301503E (pt) Derivados da cumarina com actividade inibidora de comt
PT1242410E (pt) Compostos novos
ATE302757T1 (de) Neue polyzyklische indanylimidazole mit alpha2 adrenergik aktivität
SE9903290D0 (sv) Novel compounds
ATE273985T1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
ATE286887T1 (de) Antibakterielle mittel
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
ATE206431T1 (de) Antifungal fusacandine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1280779

Country of ref document: EP

REN Ceased due to non-payment of the annual fee